There's at least one key common denominator here: tremendous growth prospects.Don't want to think too hard about your investing decisions? Then go with the stocks of highly profitable companies with strong growth prospects.Three Motley Fool contributors identified several stocks that fit this description. Here's why they think Eli Lilly (LLY 2.11%), Novo Nordisk (NVO 1.19%), and Vertex Pharmaceuticals (VRTX 0.52%) are no-brainer healthcare stocks to buy in September.The growth machine that never runs out of ...

Eli Lilly may not be an expensive stock when you consider its long-run growth prospects.Eli Lilly (LLY -0.92%) stock is up a mammoth 770% in five years. It is trading at new all-time highs in 2024 thanks to the incredible success and popularity of its diabetes and weight loss products, Mounjaro and Zepbound. But with the stock standing at a market capitalization of $850 billion and a mammoth price-to-earnings multiple of 117, you might think it ludicrous to expect it could still be a good buy.Normally, I'd ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Eli Lilly (LLY) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Lilly currently has an average br ...

Some insurers don't cover Lilly's obesity drug. The company just gave patients a way around that problem.If the price is right, sales can soar. That's true with any product -- even prescription drugs.On Tuesday, Eli Lilly (LLY -0.58%) announced a new pricing plan for its latest blockbuster drug, Zepbound. The therapy will now be available to self-pay patients at a 50% or greater discount to the list price of other GLP-1 obesity drugs. Is Lilly stock a no-brainer buy after the company's Zepbound move? Why Li ...

Eli Lilly and Company (LLY) announced the launch of single-dose vials of its popular obesity drug, Zepbound (tirzepatide), to meet supply shortages in response to high demand. These 2.5 mg and 5 mg single-dose vials are priced at least 50% lower than the list price of competing GLP-1 medicines for obesity. A four-week supply of the 2.5 mg vials has been priced at $399 while the same for the 5 mg dose will cost $549. Zepbound is presently available in a single-dose pen (autoinjector). The vials should be eas ...

替尔泊肽强劲放量引领惊艳业绩，多条管线突破促生多点开花 2024Q2 收入利润大超预期：2024Q2 公司营收 113 亿美元（同比+36%，下 同），毛利 91.3 亿美元（+40%），毛利率 80.8%（+2.2pp）。研发费用 27.1 亿美元，研发费用率 24%（-4.4pp）。营销、销售和管理费用 21.2 亿美元 （+10%），费用率 18.7%（-4.5pp）。与预期诉讼付款相关的资产减值、重 组及其他专项费用 4.35 亿美元。净利润 29.67 亿美元（+56%）净利率 26.3% （+3.4pp）。每股收益达 3.28 美元。Non-GAAP 每股收益 3.92 美元。收入端 与利润端的强劲表现大超预期。 替尔泊肽强劲放量，产能扩张持续推进：2024Q2 代谢板块收入增长 50%至 75.1 亿，最大的贡献来自替尔泊肽的放量。Mounjaro 销售环比增长 71%至 30.9 亿美元。Zepbound 销售环比增长 140%至 12.4 亿美元。市场对 GLP-1 的 需求强烈，产能是制约其放量的最主要因素。Mounjaro 自 2022 年底就被列 入 FDA 药品短缺名单，Zepbou ...

Key TakeawaysHims & Hers Health shares declined Tuesday after Eli Lilly said it would be offering a lower-priced version of its popular Zepbound weight-loss treatment.Lilly explained that the new product would be sent directly to consumers.Hims & Hers recently began offering a copycat version of Novo Nordisk's Wegovy and Ozempic, and planned to have one for Zepbound in the near future. Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs ...

ROCKVILLE, Md., Aug. 27, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2024 class in AKF’s Corporate Membership Program as a Champion-level member. Boehringer Ingelheim and Lilly will help provide financial support for AKF’s work to advance kidney disease awareness, prevention, early detection, treatment and research. “AKF is pleased to continue partnering with Boehringer Ingelheim and Lilly in our efforts to help ...

Key TakeawaysEli Lilly is launching singe-use vials of its popular weight-loss drug Zepbound, which will be half the price of previous versions of the drug.The traditional injector pens are more difficult to produce, while the vials will allow customers to use any syringe to inject the medicine.The 2.5 mg and 5 mg vials will cost $399 and $549, respectively, for a four-week supply. Eli Lilly (LLY) reached a key supply milestone Tuesday, announcing the launch of single-dose vials of Zepbound, one of the comp ...

By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . You can opt-out at any time by visiting our Preferences page or by clicking "unsubscribe" at the bottom of the email.Access your favorite topics in a personalized feed while you're on the go. download the appThanks for signing up! Go to newsletter preferencesSign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read previewOne of the biggest weight-loss drugs on the market will ...